Cargando…

Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments

BACKGROUND: Galcanezumab is a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) indicated for the preventive treatment of migraine. While galcanezumab has demonstrated efficacy in patients who did not respond to prior preventive medications in general, its efficacy in patients who did...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuruppu, Dulanji K., Tobin, Joshua, Dong, Yan, Aurora, Sheena K., Yunes-Medina, Laura, Green, A. Laine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063415/ https://www.ncbi.nlm.nih.gov/pubmed/33892641 http://dx.doi.org/10.1186/s12883-021-02196-7

Ejemplares similares

Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures
por: Schwedt, Todd J., et al.
Publicado: (2021)

Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials
por: Kuruppu, Dulanji K., et al.
Publicado: (2021)

Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment
por: Láinez, Miguel J. A., et al.
Publicado: (2021)

Galcanezumab for migraine
Publicado: (2020)

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
por: Ament, Michael, et al.
Publicado: (2021)

Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
por: Ament, Michael, et al.
Publicado: (2021)

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study
por: Detke, Holland C., et al.
Publicado: (2018)

Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review
por: Martin, Vincent, et al.
Publicado: (2020)

Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
por: Detke, Holland C., et al.
Publicado: (2019)

Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability
por: Ford, Janet H., et al.
Publicado: (2019)

Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
por: Bangs, Mark E., et al.
Publicado: (2020)

Correction to: Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
por: Bangs, Mark E., et al.
Publicado: (2020)

Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials
por: Stauffer, Virginia L., et al.
Publicado: (2019)

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis
por: Goadsby, Peter J, et al.
Publicado: (2019)

Does “wearing off” of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials
por: Ailani, Jessica, et al.
Publicado: (2022)

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine
por: Urits, Ivan, et al.
Publicado: (2020)

Photophobia and migraine outcome during treatment with galcanezumab
por: Schiano di Cola, Francesca, et al.
Publicado: (2023)

Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache
por: Andrews, J Scott, et al.
Publicado: (2021)

Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache
por: Kudrow, David, et al.
Publicado: (2020)

One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention
por: Katsuki, Masahito, et al.
Publicado: (2023)

Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE‐1, EVOLVE‐2, and REGAIN Randomized, Double‐Blind, Placebo‐Controlled Studies
por: Nichols, Russell, et al.
Publicado: (2018)

The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
por: Gklinos, Panagiotis, et al.
Publicado: (2021)

Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine
por: Ford, Janet H, et al.
Publicado: (2018)

Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination
por: Raffaelli, Bianca, et al.
Publicado: (2019)

Early Onset and Maintenance Effect of Galcanezumab in Japanese Patients with Episodic Migraine
por: Igarashi, Hisaka, et al.
Publicado: (2021)

Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine
por: di Cola, Francesca Schiano, et al.
Publicado: (2023)

Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis
por: Ailani, Jessica, et al.
Publicado: (2022)

Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies
por: Förderreuther, Stefanie, et al.
Publicado: (2018)

Response to Misused and Misleading: 100% Response Rate to Galcanezumab in Patients With Episodic Migraine
por: Rosen, Noah, et al.
Publicado: (2019)

Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
por: Takizawa, Tsubasa, et al.
Publicado: (2022)

Predictors of galcanezumab response in a real-world study of Korean patients with migraine
por: Kim, Seung Ae, et al.
Publicado: (2023)

Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double‐blind studies
por: Ailani, J., et al.
Publicado: (2019)

Galcanezumab for the Management of Migraine: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
por: Abu-Zaid, Ahmed, et al.
Publicado: (2020)

Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials
por: Gklinos, Panagiotis, et al.
Publicado: (2020)

Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine
por: Martinez, James M, et al.
Publicado: (2020)

Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis
por: Zhao, Xiuyuan, et al.
Publicado: (2020)

Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment
por: Fofi, Luisa, et al.
Publicado: (2022)

Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials
por: Ruff, D. D., et al.
Publicado: (2019)

Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm
por: Citrome, Leslie, et al.
Publicado: (2021)

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
por: Camporeale, Angelo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4hc7apjlaed9bkfo016g4bafu4